Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion

Takashi Morisaki, Kotaro Matsumoto, Hideo Kuroki, Makoto Kubo, Eishi Baba, Hideya Ohnishi, Akira Tasaki, Mitsunari Nakamura, Syoichi Inaba, Mitsuo Katano

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

We have conducted a pilot study with combined immunotherapy using autologous lymphocytes activated ex vivo and monocyte-derived dendritic cells in combination with low-dose OK-432, a streptococcal preparation, in five patients with peritoneal or pleural carcinornatosis who were resistant to standard chemotherapy. All patients were given 3 to 10 courses of the combined immunotherapy. No severe adverse reactions occurred. Effusion production was decreased in all of the patients. Significant decreases in tumor markers of both effusions and sera as well as effusion volume occurred in all of the patients. Cytological examinations revealed a marked decrease or disappearance of cancer cells in those effusions. Three patients showed increase in IFN-γ levels in the effusions. The overall prognosis of the patients was acceptable and the mean survival time was more than 9 months. The locoregional immunotherapy seems to be encouraging in view of therapeutic modality in patients who are resistant to standard chemotherapy. Our study provides a new protocol for immunotherapy and warrants further phase I/II clinical study for chemo-resistant patients with malignant effusion.

元の言語英語
ページ(範囲)4459-4465
ページ数7
ジャーナルAnticancer Research
23
発行部数6 A
出版物ステータス出版済み - 11 1 2003

Fingerprint

Picibanil
Immunotherapy
Dendritic Cells
Monocytes
Lymphocytes
Injections
Drug Therapy
Tumor Biomarkers
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion. / Morisaki, Takashi; Matsumoto, Kotaro; Kuroki, Hideo; Kubo, Makoto; Baba, Eishi; Ohnishi, Hideya; Tasaki, Akira; Nakamura, Mitsunari; Inaba, Syoichi; Katano, Mitsuo.

:: Anticancer Research, 巻 23, 番号 6 A, 01.11.2003, p. 4459-4465.

研究成果: ジャーナルへの寄稿記事

Morisaki, Takashi ; Matsumoto, Kotaro ; Kuroki, Hideo ; Kubo, Makoto ; Baba, Eishi ; Ohnishi, Hideya ; Tasaki, Akira ; Nakamura, Mitsunari ; Inaba, Syoichi ; Katano, Mitsuo. / Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion. :: Anticancer Research. 2003 ; 巻 23, 番号 6 A. pp. 4459-4465.
@article{4fe3f3b60d7540199c63d4ce37f8a9b7,
title = "Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion",
abstract = "We have conducted a pilot study with combined immunotherapy using autologous lymphocytes activated ex vivo and monocyte-derived dendritic cells in combination with low-dose OK-432, a streptococcal preparation, in five patients with peritoneal or pleural carcinornatosis who were resistant to standard chemotherapy. All patients were given 3 to 10 courses of the combined immunotherapy. No severe adverse reactions occurred. Effusion production was decreased in all of the patients. Significant decreases in tumor markers of both effusions and sera as well as effusion volume occurred in all of the patients. Cytological examinations revealed a marked decrease or disappearance of cancer cells in those effusions. Three patients showed increase in IFN-γ levels in the effusions. The overall prognosis of the patients was acceptable and the mean survival time was more than 9 months. The locoregional immunotherapy seems to be encouraging in view of therapeutic modality in patients who are resistant to standard chemotherapy. Our study provides a new protocol for immunotherapy and warrants further phase I/II clinical study for chemo-resistant patients with malignant effusion.",
author = "Takashi Morisaki and Kotaro Matsumoto and Hideo Kuroki and Makoto Kubo and Eishi Baba and Hideya Ohnishi and Akira Tasaki and Mitsunari Nakamura and Syoichi Inaba and Mitsuo Katano",
year = "2003",
month = "11",
day = "1",
language = "English",
volume = "23",
pages = "4459--4465",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 A",

}

TY - JOUR

T1 - Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion

AU - Morisaki, Takashi

AU - Matsumoto, Kotaro

AU - Kuroki, Hideo

AU - Kubo, Makoto

AU - Baba, Eishi

AU - Ohnishi, Hideya

AU - Tasaki, Akira

AU - Nakamura, Mitsunari

AU - Inaba, Syoichi

AU - Katano, Mitsuo

PY - 2003/11/1

Y1 - 2003/11/1

N2 - We have conducted a pilot study with combined immunotherapy using autologous lymphocytes activated ex vivo and monocyte-derived dendritic cells in combination with low-dose OK-432, a streptococcal preparation, in five patients with peritoneal or pleural carcinornatosis who were resistant to standard chemotherapy. All patients were given 3 to 10 courses of the combined immunotherapy. No severe adverse reactions occurred. Effusion production was decreased in all of the patients. Significant decreases in tumor markers of both effusions and sera as well as effusion volume occurred in all of the patients. Cytological examinations revealed a marked decrease or disappearance of cancer cells in those effusions. Three patients showed increase in IFN-γ levels in the effusions. The overall prognosis of the patients was acceptable and the mean survival time was more than 9 months. The locoregional immunotherapy seems to be encouraging in view of therapeutic modality in patients who are resistant to standard chemotherapy. Our study provides a new protocol for immunotherapy and warrants further phase I/II clinical study for chemo-resistant patients with malignant effusion.

AB - We have conducted a pilot study with combined immunotherapy using autologous lymphocytes activated ex vivo and monocyte-derived dendritic cells in combination with low-dose OK-432, a streptococcal preparation, in five patients with peritoneal or pleural carcinornatosis who were resistant to standard chemotherapy. All patients were given 3 to 10 courses of the combined immunotherapy. No severe adverse reactions occurred. Effusion production was decreased in all of the patients. Significant decreases in tumor markers of both effusions and sera as well as effusion volume occurred in all of the patients. Cytological examinations revealed a marked decrease or disappearance of cancer cells in those effusions. Three patients showed increase in IFN-γ levels in the effusions. The overall prognosis of the patients was acceptable and the mean survival time was more than 9 months. The locoregional immunotherapy seems to be encouraging in view of therapeutic modality in patients who are resistant to standard chemotherapy. Our study provides a new protocol for immunotherapy and warrants further phase I/II clinical study for chemo-resistant patients with malignant effusion.

UR - http://www.scopus.com/inward/record.url?scp=0345303903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345303903&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 4459

EP - 4465

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 A

ER -